Advertisement

Thrombotic Thrombocytopenic Purpura and the Atypical Hemolytic Uremic Syndrome

An Update

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Hematology/Oncology Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Tsai H.M.
        Thrombotic thrombocytopenic purpura: a thrombotic disorder caused by ADAMTS13 deficiency.
        Hematol Oncol Clin North Am. 2007; 21 (v): 609-632
        • George J.N.
        How I treat patients with thrombotic thrombocytopenic purpura: 2010.
        Blood. 2010; 116: 4060-4069
        • Tsai H.M.
        Autoimmune thrombotic microangiopathy: advances in pathogenesis, diagnosis, and management.
        Semin Thromb Hemost. 2012; 38: 469-482
        • Reti M.
        • Farkas P.
        • Csuka D.
        • et al.
        Complement activation in thrombotic thrombocytopenic purpura.
        J Thromb Haemost. 2012; 10: 791-798
        • Sanchez-Luceros A.
        • Farias C.E.
        • Amaral M.M.
        • et al.
        von Willebrand factor-cleaving protease (ADAMTS13) activity in normal non-pregnant women, pregnant and post-delivery women.
        Thromb Haemost. 2004; 92: 1320-1326
        • Cao W.J.
        • Niiya M.
        • Zheng X.W.
        • et al.
        Inflammatory cytokines inhibit ADAMTS13 synthesis in hepatic stellate cells and endothelial cells.
        J Thromb Haemost. 2008; 6: 1233-1235
        • Motto D.G.
        • Chauhan A.K.
        • Zhu G.
        • et al.
        Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13-deficient mice.
        J Clin Invest. 2005; 115: 2752-2761
        • Banno F.
        • Kokame K.
        • Okuda T.
        • et al.
        Complete deficiency in ADAMTS13 is prothrombotic, but it alone is not sufficient to cause thrombotic thrombocytopenic purpura.
        Blood. 2006; 107: 3161-3166
        • Schiviz A.
        • Wuersch K.
        • Piskernik C.
        • et al.
        A new mouse model mimicking thrombotic thrombocytopenic purpura: correction of symptoms by recombinant human ADAMTS13.
        Blood. 2012; 119: 6128-6135
        • Feys H.B.
        • Roodt J.
        • Vandeputte N.
        • et al.
        Thrombotic thrombocytopenic purpura directly linked with ADAMTS13 inhibition in the baboon (Papio ursinus).
        Blood. 2010; 116: 2005-2010
        • Ermini L.
        • Goodship T.H.
        • Strain L.
        • et al.
        Common genetic variants in complement genes other than CFH, CD46 and the CFHRs are not associated with aHUS.
        Mol Immunol. 2012; 49: 640-648
        • Heurich M.
        • Martinez-Barricarte R.
        • Francis N.J.
        • et al.
        Common polymorphisms in C3, factor B, and factor H collaborate to determine systemic complement activity and disease risk.
        Proc Natl Acad Sci U S A. 2011; 108: 8761-8766
        • Dragon-Durey M.A.
        • Sethi S.K.
        • Bagga A.
        • et al.
        Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome.
        J Am Soc Nephrol. 2010; 21: 2180-2187
        • Noris M.
        • Caprioli J.
        • Bresin E.
        • et al.
        Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype.
        Clin J Am Soc Nephrol. 2010; 5: 1844-1859
        • Fakhouri F.
        • Roumenina L.
        • Provot F.
        • et al.
        Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations.
        J Am Soc Nephrol. 2010; 21: 859-867
        • Tsai H.M.
        • Rice L.
        • Sarode R.
        • et al.
        Antibody inhibitors to von Willebrand factor metalloproteinase and increased binding of von Willebrand factor to platelets in ticlopidine-associated thrombotic thrombocytopenic purpura.
        Ann Intern Med. 2000; 132: 794-799
        • Hirata S.
        • Okamoto H.
        • Ohta S.
        • et al.
        Deficient activity of von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura in the setting of adult-onset Still's disease.
        Rheumatology (Oxford). 2006; 45: 1046-1047
        • Torok N.
        • Niazi M.
        • Al A.Y.
        • et al.
        Thrombotic thrombocytopenic purpura associated with anti-glomerular basement membrane disease.
        Nephrol Dial Transplant. 2010; 25: 3446-3449
        • Salmon J.E.
        • Heuser C.
        • Triebwasser M.
        • et al.
        Mutations in complement regulatory proteins predispose to preeclampsia: a genetic analysis of the PROMISSE cohort.
        PLoS Med. 2011; 8: e1001013
        • Tsai H.M.
        Mechanisms of microvascular thrombosis in thrombotic thrombocytopenic purpura.
        Kidney Int Suppl. 2009; : S11-S14
        • Manea M.
        • Kristoffersson A.
        • Schneppenheim R.
        • et al.
        Podocytes express ADAMTS13 in normal renal cortex and in patients with thrombotic thrombocytopenic purpura.
        Br J Haematol. 2007; 138: 651-662
        • Gutterman L.A.
        • Kloster B.
        • Tsai H.M.
        Rituximab therapy for refractory thrombotic thrombocytopenic purpura.
        Blood Cells Mol Dis. 2002; 28: 385-391
        • Elliott M.A.
        • Heit J.A.
        • Pruthi R.K.
        • et al.
        Rituximab for refractory and or relapsing thrombotic thrombocytopenic purpura related to immune-mediated severe ADAMTS13-deficiency: a report of four cases and a systematic review of the literature.
        Eur J Haematol. 2009; 83: 365-372
        • Scully M.
        • McDonald V.
        • Cavenagh J.
        • et al.
        A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura.
        Blood. 2011; 118: 1746-1753
        • Hart D.
        • Sayer R.
        • Miller R.
        • et al.
        Human immunodeficiency virus associated thrombotic thrombocytopenic purpura–favourable outcome with plasma exchange and prompt initiation of highly active antiretroviral therapy.
        Br J Haematol. 2011; 153: 515-519
        • Cataland S.R.
        • Jin M.
        • Lin S.
        • et al.
        Effect of prophylactic cyclosporine therapy on ADAMTS13 biomarkers in patients with idiopathic thrombotic thrombocytopenic purpura.
        Am J Hematol. 2008; 83: 911-915
        • Loirat C.
        • Babu S.
        • Furman R.
        • et al.
        Eculizumab efficacy and safety inpatients with atypical hemolyticuremic syndrome (aHUS) resistanttoplasmaexchange/infusion.
        Haematologica. 2011; 96: S2-S979
        • Loirat C.
        • Muus P.
        • Legendre C.
        • et al.
        A phase II study of eculizumab in patients with atypical hemolyticuremic syndrome receiving chronic plasma exchange/infusion.
        Haematologica. 2011; 96: S2-S980
        • Kelly R.J.
        • Hill A.
        • Arnold L.M.
        • et al.
        Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival.
        Blood. 2011; 117: 6786-6792
        • Saland J.M.
        • Ruggenenti P.
        • Remuzzi G.
        Liver-kidney transplantation to cure atypical hemolytic uremic syndrome.
        J Am Soc Nephrol. 2009; 20: 940-949
        • Weitz M.
        • Amon O.
        • Bassler D.
        • et al.
        Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic syndrome.
        Pediatr Nephrol. 2011; 26: 1325-1329
        • Nester C.
        • Stewart Z.
        • Myers D.
        • et al.
        Pre-emptive eculizumab and plasmapheresis for renal transplant in atypical hemolytic uremic syndrome.
        Clin J Am Soc Nephrol. 2011; 6: 1488-1494